Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 92

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy

Wang, Shuai, Chen, Fen-Er · 2022 · European Journal of Medicinal Chemistry

Abstract

Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has been highly pursued by many academic laboratories and pharmaceutical companies as a promising strategy for cancer therapy. To date, based on the explanation of the cocrystal structure of MDM2 with p53, many highly potent and selective small-molecule MDM2 inhibitors have been successfully discovered and nine of them are currently under different clinical trials for cancer therapy. Herein, we will review the function of MDM2 and provide a comprehensive and updated overview of small-molecule MDM2 inhibitors in different clinical phases for cancer therapy, especially focusing on the identification and optimization, and preclinical/clinical studies of these clinical-stage MDM2 inhibitors. Challenges regarding acquired resistance and potential toxicity of MDM2 inhibitors to normal tissues and outlook are also briefly discussed, which will further guide the design of new small-molecule MDM2 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2022.114334

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 79

  1. Bieging, 2014, Unravelling mechanisms of p53-mediated tumour suppression, Nat. Rev. Cancer, 14, 359, 10.1038/nrc3711 · DOI · Paper page
  2. Vousden, 2002, Live or let die: the cell's response to p53, Nat. Rev. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
  3. Levine, 1997, p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
  4. Wu, 1997, Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene, Mol. Med., 3, 441, 10.1007/BF03401691 · DOI · Paper page
  5. Wu, 1993, The p53-mdm-2 autoregulatory feedback loop, Genes Dev., 7, 1126, 10.1101/gad.7.7a.1126 · DOI · Paper page
  6. Freedman, 1999, Functions of the MDM2 oncoprotein, Cell. Mol. Life Sci., 55, 96, 10.1007/s000180050273 · DOI · Paper page
  7. Juven-Gershon, 1999, Mdm2: the ups and downs, Mol. Med., 5, 71, 10.1007/BF03402141 · DOI · Paper page
  8. Bond, 2005, MDM2 is a central node in the p53 pathway: 12 years and counting, Curr. Cancer Drug Targets, 5, 3, 10.2174/1568009053332627 · DOI · Paper page
  9. Capoulade, 1998, Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells, Oncogene, 16, 1603, 10.1038/sj.onc.1201702 · DOI
  10. Prives, 1999, The p53 pathway, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
  11. Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001, 10.1038/nature06526 · DOI · Paper page
  12. Fuller, 2009, Predicting druggable binding sites at the protein-protein interface, Drug Discov. Today, 14, 155, 10.1016/j.drudis.2008.10.009 · DOI · Paper page
  13. Zak, 2013, Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present), Expert Opin. Ther. Pat., 23, 425, 10.1517/13543776.2013.765405 · DOI
  14. Wang, 2012, Small molecule agents targeting the p53-MDM2 pathway for cancer therapy, Med. Res. Rev., 32, 1159, 10.1002/med.20236 · DOI
  15. Khoury, 2011, The p53-MDM2/MDMX axis - a chemotype perspective, MedChemComm, 2, 246, 10.1039/c0md00248h · DOI
  16. Popowicz, 2011, The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious, Angew. Chem., 50, 2680, 10.1002/anie.201003863 · DOI · Paper page
  17. Tisato, 2017, MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer, J. Hematol. Oncol., 10, 133, 10.1186/s13045-017-0500-5 · DOI · Paper page
  18. Vu, 2013, Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development, ACS Med. Chem. Lett., 4, 466, 10.1021/ml4000657 · DOI · Paper page
  19. Tovar, 2013, MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models, Cancer Res., 73, 2587, 10.1158/0008-5472.CAN-12-2807 · DOI · Paper page
  20. Hoffman-Luca, 2015, Elucidation of acquired resistance to Bcl-2 and MDM2 inhibitors in acute leukemia in vitro and in vivo, Clin. Cancer Res., 21, 2558, 10.1158/1078-0432.CCR-14-2506 · DOI · Paper page
  21. Bauer, 2018, A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L), J. Clin. Oncol., 36, 11514, 10.1200/JCO.2018.36.15_suppl.11514 · DOI
  22. Yi, 2018, A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma, J. Exp. Clin. Cancer Res., 37, 97, 10.1186/s13046-018-0765-8 · DOI · Paper page
  23. Valat, 2014, Abstract 1798: mechanistic study of NVP-CGM097: a potent, selective and species specific inhibitor of p53-Mdm2, Cancer Res., 74, 1798, 10.1158/1538-7445.AM2014-1798 · DOI
  24. Furet, 2016, Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument, Bioorg. Med. Chem. Lett, 26, 4837, 10.1016/j.bmcl.2016.08.010 · DOI · Paper page
  25. Ferretti, 2016, Abstract 1224: insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials, Cancer Res., 76, 1224, 10.1158/1538-7445.AM2016-1224 · DOI
  26. Reutershan, 2021, Discovery of MK-4688: an efficient inhibitor of the HDM2–p53 protein–protein interaction, J. Med. Chem., 64, 16213, 10.1021/acs.jmedchem.1c01524 · DOI
  27. Wade, 2013, MDM2, MDMX and p53 in oncogenesis and cancer therapy, Nat. Rev. Cancer, 13, 83, 10.1038/nrc3430 · DOI · Paper page
  28. Riedinger, 2009, Inhibitors of MDM2 and MDMX: a structural perspective, Future Med. Chem., 1, 1075, 10.4155/fmc.09.75 · DOI
  29. Millard, 2011, Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update, Curr. Pharmaceut. Des., 17, 536, 10.2174/138161211795222649 · DOI
  30. Lane, 2010, p53-based cancer therapy, Cold Spring Harbor Perspect. Biol., 2, 10.1101/cshperspect.a001222 · DOI · Paper page
  31. Dickens, 2010, Small-molecule inhibitors of MDM2 as new anticancer therapeutics, Semin. Cancer Biol., 20, 10, 10.1016/j.semcancer.2009.10.003 · DOI
  32. Khoo, 2014, Drugging the p53 pathway: understanding the route to clinical efficacy, Nat. Rev. Drug Discov., 13, 217, 10.1038/nrd4236 · DOI · Paper page
  33. Liu, 2019, The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy, Eur. J. Med. Chem., 176, 92, 10.1016/j.ejmech.2019.05.018 · DOI
  34. Konopleva, 2020, MDM2 inhibition: an important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
  35. Wang, 2021, FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application, Eur. J. Med. Chem., 214, 10.1016/j.ejmech.2021.113218 · DOI
  36. Wang, 2021, Discovery of the triazolo[1,5-a]pyrimidine-based derivative WS-898 as a highly efficacious and orally bioavailable ABCB1 inhibitor capable of overcoming multidrug resistance, J. Med. Chem., 64, 16187, 10.1021/acs.jmedchem.1c01498 · DOI
  37. Wang, 2020, Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators, J. Med. Chem., 63, 15979, 10.1021/acs.jmedchem.0c01741 · DOI
  38. Wang, 2019, Development of highly potent, selective, and cellular active triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1–UBC12 protein–protein interaction, J. Med. Chem., 62, 2772, 10.1021/acs.jmedchem.9b00113 · DOI
  39. Lu, 2020, Drug repurposing: discovery of troxipide analogs as potent antitumor agents, Eur. J. Med. Chem., 202, 10.1016/j.ejmech.2020.112471 · DOI
  40. Wang, 2020, Asymmetric catalysis in synthetic strategies for chiral benzothiazepines, Green Synthesis Catalys., 1, 12, 10.1016/j.gresc.2020.05.005 · doi:10.1016/j.gresc.2020.05.005
  41. Tang, 2020, Asymmetric catalytic hydrogenation of imines and enamines in natural product synthesis, Green Synthesis Catalys., 1, 26, 10.1016/j.gresc.2020.05.006 · doi:10.1016/j.gresc.2020.05.006
  42. Yang, 2021, Carbon dioxide cycle via electrocatalysis: electrochemical carboxylation of CO2 and decarboxylative functionalization of carboxylic acids, Green Synthesis Catalys., 2, 19, 10.1016/j.gresc.2021.01.009 · DOI
  43. Yan, 2021, Harnessing noncovalent interaction of chalcogen bond in organocatalysis: from the catalyst point of view, Green Synthesis Catalys., 2, 329, 10.1016/j.gresc.2021.08.002 · doi:10.1016/j.gresc.2021.08.002
  44. Picksley, 1993, The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?, Bioessays : News Rev. Mol. Cellular Dev. Biol., 15, 689, 10.1002/bies.950151008 · DOI · Paper page
  45. Fang, 2000, Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53, J. Biol. Chem., 275, 8945, 10.1074/jbc.275.12.8945 · DOI · Paper page
  46. Kubbutat, 1998, Regulation of Mdm2-directed degradation by the C terminus of p53, Mol. Cell Biol., 18, 5690, 10.1128/MCB.18.10.5690 · DOI · Paper page
  47. Lai, 2001, Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization, J. Biol. Chem., 276, 31357, 10.1074/jbc.M011517200 · DOI · Paper page
  48. Grossman, 2003, Polyubiquitination of p53 by a ubiquitin ligase activity of p300, Science, 300, 342, 10.1126/science.1080386 · DOI · Paper page
  49. Chen, 1993, Mapping of the p53 and mdm-2 interaction domains, Mol. Cell Biol., 13, 4107
  50. Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
  51. Lai, 2000, Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length, Arch. Biochem. Biophys., 381, 278, 10.1006/abbi.2000.1998 · DOI
  52. Dumaz, 1999, Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2, EMBO J., 18, 7002, 10.1093/emboj/18.24.7002 · DOI · Paper page
  53. Maya, 2001, ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage, Genes Dev., 15, 1067, 10.1101/gad.886901 · DOI · Paper page
  54. Tao, 1999, P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2, Proc. Natl. Acad. Sci. U.S.A., 96, 6937, 10.1073/pnas.96.12.6937 · DOI · Paper page
  55. Weber, 1999, Nucleolar Arf sequesters Mdm2 and activates p53, Nat. Cell Biol., 1, 20, 10.1038/8991 · DOI · Paper page
  56. Gu, 2002, Mutual dependence of MDM2 and MDMX in their functional inactivation of p53, J. Biol. Chem., 277, 19251, 10.1074/jbc.C200150200 · DOI · Paper page
  57. Lohrum, 2003, Regulation of HDM2 activity by the ribosomal protein L11, Cancer Cell, 3, 577, 10.1016/S1535-6108(03)00134-X · DOI · Paper page
  58. Mayo, 2001, A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus, Proc. Natl. Acad. Sci. U.S.A., 98, 11598, 10.1073/pnas.181181198 · DOI · Paper page
  59. Gottlieb, 2002, Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis, Oncogene, 21, 1299, 10.1038/sj.onc.1205181 · DOI · Paper page
  60. Zhou, 2001, HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation, Nat. Cell Biol., 3, 973, 10.1038/ncb1101-973 · DOI · Paper page
  61. Freeman, 2003, PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms, Cancer Cell, 3, 117, 10.1016/S1535-6108(03)00021-7 · DOI · Paper page
  62. Popowicz, 2010, Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery, Cell Cycle, 9, 1104, 10.4161/cc.9.6.10956 · DOI · Paper page
  63. Chen, 2014, Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists, J. Med. Chem., 57, 4962, 10.1021/jm401798r · DOI
  64. Zhao, 2013, A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice, J. Med. Chem., 56, 5553, 10.1021/jm4005708 · DOI · Paper page
  65. Aguilar, 2014, Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles, J. Med. Chem., 57, 10486, 10.1021/jm501541j · DOI
  66. Rew, 2012, Structure-based design of novel inhibitors of the MDM2–p53 interaction, J. Med. Chem., 55, 4936, 10.1021/jm300354j · DOI · Paper page
  67. Ye, 2015, Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation, Xenobiotica, 45, 681, 10.3109/00498254.2015.1010632 · DOI
  68. Gessier, 2015, Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode, Bioorg. Med. Chem. Lett, 25, 3621, 10.1016/j.bmcl.2015.06.058 · DOI
  69. Stachyra-Valat, 2016, Abstract 1239: NVP-HDM201: biochemical and biophysical profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2, Cancer Res., 76, 1239, 10.1158/1538-7445.AM2016-1239 · DOI · Paper page
  70. Holzer, 2016, Discovery of NVP-HDM201-first disclosure of a next-generation Mdm2 inhibitor with superior characteristics, Cancer Res., 76, 4855, 10.1158/1538-7445.AM2016-4855 · DOI
  71. Ravandi, 2016, A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML), Leuk. Res., 48, 92, 10.1016/j.leukres.2016.07.004 · DOI · Paper page
  72. Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929 · DOI · Paper page
  73. Li, 2016, Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies, Drug Resist. Updates, 27, 14, 10.1016/j.drup.2016.05.001 · DOI · Paper page
  74. Dong, 2020, Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update, Drug Resist. Updates, 49, 10.1016/j.drup.2020.100681 · DOI · Paper page
  75. Wang, 2020, Structure-based design, synthesis, and biological evaluation of new triazolo[1,5-a]pyrimidine derivatives as highly potent and orally active ABCB1 modulators, J. Med. Chem., 63, 15979, 10.1021/acs.jmedchem.0c01741 · DOI
  76. Ng, 2018, Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models, Nat. Commun., 9, 2024, 10.1038/s41467-018-04356-9 · DOI
  77. Wurz, 2019, Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors, J. Med. Chem., 62, 445, 10.1021/acs.jmedchem.8b01945 · DOI
  78. Wang, 2021, Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries, Eur. J. Med. Chem., 219, 113425, 10.1016/j.ejmech.2021.113425 · DOI · Paper page
  79. Uy, 2020, Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia, Invest. N. Drugs, 38, 1430, 10.1007/s10637-020-00907-4 · DOI

Cited by

See all 92

Metadata

Authors
Wang, S., & Chen, F.-E.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2022-06
Volume
236
Pages
114334
ISSN
0223-5234
Cited by
92
References
39
Language
en
Funders
  • Shanghai Municipal Natural Science Foundation (13ZR1402200)
  • China Association for Science and Technology (2017QNRC061)
  • National Natural Science Foundation of China (21372050, 22077018)
  • Fudan University (JIH1615060)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. https://app.cochat.ai/papers/10.1016/j.ejmech.2022.114334
The paper
Wang, S., & Chen, F.-E. (2022). Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2022.114334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.